TP53 rs121912620: Understanding This Benign Genetic Variant
The rs121912620 variant is a rare, benign genetic polymorphism located within the TP53 gene. While it was historically misclassified in some databases as a somatic mutation linked to cancer, current research identifies it as a harmless variation with no clinical significance.
What each genotype means
Common benign genotype
This genotype represents the most common form of this specific location in the TP53 gene. Research indicates this variant is a benign polymorphism and is not associated with an increased risk of cancer or Li-Fraumeni syndrome.
This is the most frequent genotype observed across all major global populations.
Rare benign carrier
You carry one copy of this rare, benign polymorphism. Current scientific literature classifies this as a non-pathogenic variant that was previously misidentified as a somatic tumor mutation in some databases.
This genotype is rare and found at a very low frequency in the general population.
Rare benign genotype
You carry two copies of this rare, benign polymorphism. There is no evidence to suggest that this genotype contributes to disease risk or affects the function of the TP53 protein.
This genotype is extremely rare across all studied ancestral groups.
What is rs121912620?
The variant rs121912620 is a single nucleotide polymorphism (SNP) found within the TP53 gene. In genomics, a SNP represents a change in a single building block of DNA, known as a nucleotide. This specific variant has been the subject of careful re-evaluation in recent years. Historically, it appeared in some locus-specific databases as a potential somatic mutation—a change that occurs in non-reproductive cells and is often associated with tumor development. However, rigorous analysis using modern genomic standards has clarified that this variant is actually a benign polymorphism. This means it is a natural, harmless variation in the human genetic code that does not cause disease or affect the function of the protein it encodes. Its presence in older literature as a 'tumor variant' is now widely considered an error in classification, highlighting the importance of continuous updates in genomic databases.
The Role of the TP53 Gene
The TP53 gene provides instructions for making a protein called p53, which acts as a tumor suppressor. This protein is often referred to as the 'guardian of the genome' because it plays a critical role in preventing cells from growing and dividing in an uncontrolled or abnormal way. When DNA damage occurs, the p53 protein helps determine whether the cell should repair the damage or undergo a process called apoptosis, which is programmed cell death. By regulating these processes, the p53 protein helps maintain genomic stability and prevents the formation of tumors. Inherited pathogenic variants in TP53 can lead to Li-Fraumeni syndrome, a condition that significantly increases the risk of developing various cancers. Because of the gene's vital function, any variant identified within it is scrutinized heavily by researchers to distinguish between harmless polymorphisms and those that truly disrupt the protein's protective capabilities.
Research and Evidence Strength
The evidence regarding rs121912620 is categorized as moderate in terms of its classification history, primarily because it required significant effort to correct its status in public databases. Scientific consensus now classifies this variant as benign. The confusion stemmed from its initial inclusion in databases that track somatic mutations found in cancer tissues. When researchers compared these findings against large-scale population databases like gnomAD, they observed that the variant exists in healthy individuals without the associated clinical outcomes of TP53-related disorders. Consequently, the scientific community has reclassified it to reflect its lack of pathogenicity. It is important to note that while this variant is benign, the TP53 gene itself remains a high-priority area for cancer research. Any individual concerned about their genetic risk for cancer should rely on clinical genetic testing and professional counseling rather than interpreting individual benign SNPs found in personal genomic reports.
What You Can Do With This Information
Understanding that rs121912620 is a benign polymorphism is a lesson in the complexity of genomic interpretation. For a reader, this information serves as a reminder that not every variant listed in a database is a cause for concern. If you encounter this variant in a personal genetic report, it is generally considered a neutral finding that does not require medical intervention or lifestyle changes. You cannot use this information to diagnose a condition or predict a future health outcome. Because genomic science is constantly evolving, databases are updated frequently to correct past errors. If you have concerns about your family history of cancer or your personal health, the most effective step is to consult with a certified genetic counselor or a physician. They can provide context based on your entire genetic profile and clinical history, ensuring that you receive accurate information rather than relying on isolated, benign data points.
How common is this variant?
The rs121912620 variant is classified as rare across global populations, appearing at a very low frequency in large-scale genomic databases.
Frequently asked questions
Is rs121912620 linked to cancer?
No. While it was previously misidentified in some databases as a somatic tumor variant, current research confirms that rs121912620 is a benign polymorphism and is not associated with cancer risk.
Should I be worried if I have this variant?
No, there is no reason for concern. This variant is considered harmless and does not affect the function of the TP53 protein or your health.
Why did some databases call it a tumor variant?
Early genomic databases sometimes included somatic mutations found in tumor samples without sufficient filtering. Subsequent studies of healthy populations proved that this specific variant is a natural, benign part of human genetic diversity.
Does this variant require medical follow-up?
No. Because it is a benign, non-pathogenic variant, it does not require any medical follow-up, testing, or changes to your healthcare routine.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912620?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TP53
This pathogenic germline variant in the TP53 gene is associated with Li-Fraumeni syndrome, a condition characterized by a high risk of early-onset cancers.
Pathogenic missense variant (p.Arg248Gln) associated with Li-Fraumeni syndrome.
Functional codon 72 polymorphism (Arg72Pro) affecting apoptotic capability and associated with differential susceptibility to multiple cancer types.
Functional 3' UTR polyadenylation signal polymorphism altering TP53 transcription termination, showing population-specific baseline carrier frequencies across global groups.
Pathogenic hotspot variant (p.Arg273His) in TP53 predisposing carriers to early-onset sarcomas, breast cancers, and leukemias.
Li-Fraumeni syndrome missense variant (p.Arg248Trp) causing loss of tumor suppressor function and multi-cancer predisposition.